nach oben

Erschienen in:

06.12.2023 | Review

Prevalence of BRAF p.V600E and Detection Methods in Benign Mixed and Malignant Odontogenic Tumors: A Systematic Review

verfasst von: Raisa Jordana Geraldine Severino-Lazo, Marianne de Vasconcelos Carvalho, Camilla Porto Campello, Sandra Lúcia Dantas Moraes, Belmiro Cavalcanti do Egito Vasconcelos, Eduardo Piza Pellizzer

Erschienen in: Head and Neck Pathology | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

The BRAF p.V600E genetic variant facilitates the pathogenesis of various tumors by triggering tumor proliferation and progression. The aim of this study was to analyze the prevalence of BRAF p.V600E in benign mixed epithelial and mesenchymal and malignant odontogenic tumors. In addition, we discussed the different detection methods used to assess for aberrant BRAF.

Methods

This systematic review followed the PRISMA guidelines and was registered in Prospero (CRD42023445689). A comprehensive search of the PubMed/MEDLINE, Scopus, Web of Science, and Embase electronic databases was performed to answer the question “What is the prevalence of the BRAF p.V600E mutation in benign mixed and malignant odontogenic tumors?” The methodological quality of the selected studies was assessed using the JBI’s Critical Appraisal Tool.

Results

Initially, 387 records were identified, but only 11 articles met the inclusion criteria. A total of 70 patients with benign mixed epithelial and mesenchymal odontogenic tumors and 63 with malignant odontogenic tumors were included in the analysis. We found that the BRAF p.V600E mutation had a prevalence of 31.42% in mixed tumors and 26.98% in malignant odontogenic tumors. Moreover, immunohistochemistry showed high concordance with DNA-based molecular methods.

Conclusion

In general, the BRAF p.V600E variant exhibited a prominent prevalence in mixed and malignant odontogenic tumors. However, most of the findings are based on small cohorts of patients and further studies with larger cohorts are needed.

Nur mit Berechtigung zugänglich

Gomes IP, Bastos VC, Guimarães LM, Gomes CC (2023) The molecular basis of odontogenic cysts and tumours. J Oral Pathol Med. https://doi.org/10.1111/jop.13401CrossRefPubMed

Oh KY, Kim JH, Cho SD et al (2022) BRAF V600E and previously unidentified KRAS G12C mutations in odontogenic tumors may affect MAPK activation differently depending on tumor type. Genes Chromosomes Cancer 61:481–490. https://doi.org/10.1002/gcc.23040CrossRefPubMed

WHO Classification of Tumours Editorial Board (2022) Head and neck tumours, 5th edn. International Agency for Research on Cancer, Lyon

Togni L, Zizzi A, Mazzucchelli R et al (2022) Identification of BRAF V600E mutation in odontogenic tumors by high-performance MALDI-TOF analysis. Int J Oral Sci. https://doi.org/10.1038/s41368-022-00170-8CrossRefPubMedPubMedCentral

Diniz MG, Gomes CC, Guimarães BVA et al (2015) Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours. Tumor Biol 36:5649–5653. https://doi.org/10.1007/s13277-015-3238-0CrossRef

Seki-Soda M, Sano T, Ito K et al (2020) An immunohistochemical and genetic study of BRAFV600E mutation in Japanese patients with ameloblastoma. Pathol Int 70:224–230. https://doi.org/10.1111/pin.12899CrossRefPubMed

Buettner R, Gültekin SE (2022) Molecular diagnostics in odontogenic tumors. Pathologie 43:81–85. https://doi.org/10.1007/s00292-022-01152-7CrossRefPubMed

Oh KY, Cho SD, Yoon HJ et al (2021) Discrepancy between immunohistochemistry and sequencing for BRAF V600E in odontogenic tumours: comparative analysis of two VE1 antibodies. J Oral Pathol Med 50:85–91. https://doi.org/10.1111/jop.13108CrossRefPubMed

Brunner P, Bihl M, Jundt G et al (2015) BRAF p.V600E mutations are not unique to ameloblastoma and are shared by other odontogenic tumors with ameloblastic morphology. Oral Oncol. https://doi.org/10.1016/j.oraloncology.2015.07.010CrossRefPubMed

10.

Coura BP, Bernardes VF, de Sousa SF et al (2020) Targeted next-generation sequencing and allele-specific quantitative PCR of laser capture microdissected samples uncover molecular differences in mixed odontogenic tumors. J Mol Diagn 22:1393–1399. https://doi.org/10.1016/j.jmoldx.2020.08.005CrossRefPubMed

11.

Brown NA, Rolland D, McHugh JB et al (2014) Activating FGFR2-RAS-BRAF mutations in ameloblastoma. Clin Cancer Res 20:5517–5526. https://doi.org/10.1158/1078-0432.CCR-14-1069CrossRefPubMed

12.

Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/bmj.n71CrossRefPubMedPubMedCentral

13.

Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174. https://doi.org/10.2307/2529310CrossRefPubMed

14.

Bologna-Molina R, Mikami T, Pereira-Prado V et al (2017) Primordial odontogenic tumor: An immunohistochemical profile. Med Oral Patol Oral Cir Bucal 22:e314–e323. https://doi.org/10.4317/medoral.21859CrossRefPubMedPubMedCentral

15.

Diniz MG, Duarte AP, Villacis RA et al (2017) Rare copy number alterations and copy-neutral loss of heterozygosity revealed in ameloblastomas by high-density whole-genome microarray analysis. J Oral Pathol Med 46:371–376. https://doi.org/10.1111/jop.12505CrossRefPubMed

16.

Niu Z, Li Y, Chen W et al (2020) Study on clinical and biological characteristics of ameloblastic carcinoma. Orphanet J Rare Dis. https://doi.org/10.1186/s13023-020-01603-5CrossRefPubMedPubMedCentral

17.

Magalhães MCSV, Felix FA, Guimarães LM et al (2022) Interrogation of TERT promoter hotspot mutations in ameloblastoma and ameloblastic carcinoma. J Oral Pathol Med. https://doi.org/10.1111/jop.13364CrossRefPubMed

18.

Agaimy A, Skalova A, Franchi A et al (2020) Ameloblastic fibrosarcoma: clinicopathological and molecular analysis of seven cases highlighting frequent BRAF and occasional NRAS mutations. Histopathology 76:814–821. https://doi.org/10.1111/his.14053CrossRefPubMed

19.

Diniz MG, Gomes CC, de Sousa SF et al (2017) Oncogenic signalling pathways in benign odontogenic cysts and tumours. Oral Oncol 72:165–173. https://doi.org/10.1016/j.oraloncology.2017.07.021CrossRefPubMed

20.

Martins-de-Barros AV, Silva CCG, Gonçalves KKN et al (2023) Does BRAF V600E mutation affect recurrence rate of ameloblastomas? Systematic review and meta-analysis. J Oral Pathol Med 52:701–709CrossRefPubMed

21.

Guimarães LM, Coura BP, Gomez RS, Gomes CC (2021) The molecular pathology of odontogenic tumors: expanding the spectrum of MAPK pathway driven tumors. Front Oral Health. https://doi.org/10.3389/froh.2021.740788CrossRefPubMedPubMedCentral

22.

Soluk-Tekkesin M, Wright JM (2022) The World Health Organization classification of odontogenic lesions: a summary of the changes of the 2022 (5th) edition. Turk Patoloji Derg 38:168–184. https://doi.org/10.5146/tjpath.2022.01573CrossRefPubMedPubMedCentral

23.

Soluk-Tekkeşin M, Wright JM (2018) The world health organization classification of odontogenic lesions: a summary of the changes of the 2017 (4th) edition. Turk Patoloji Derg 34:1–18. https://doi.org/10.5146/tjpath.2017.01410CrossRef

24.

Martins-de-Barros AV, dos Anjos RS, Silva CCG et al (2022) Diagnostic accuracy of immunohistochemistry compared with molecular tests for detection of BRAF V600E mutation in ameloblastomas: systematic review and meta-analysis. J Oral Pathol Med 51:223–230. https://doi.org/10.1111/jop.13278CrossRefPubMed

Titel: Prevalence of BRAF p.V600E and Detection Methods in Benign Mixed and Malignant Odontogenic Tumors: A Systematic Review
verfasst von: Raisa Jordana Geraldine Severino-Lazo
Marianne de Vasconcelos Carvalho
Camilla Porto Campello
Sandra Lúcia Dantas Moraes
Belmiro Cavalcanti do Egito Vasconcelos
Eduardo Piza Pellizzer
Publikationsdatum: 06.12.2023
Verlag: Springer US
Erschienen in: Head and Neck Pathology / Ausgabe 4/2023
Elektronische ISSN: 1936-0568
DOI: https://doi.org/10.1007/s12105-023-01601-6

Springer Medizin

Prevalence of BRAF p.V600E and Detection Methods in Benign Mixed and Malignant Odontogenic Tumors: A Systematic Review

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2023

Human Papillomavirus-Associated Oral Epithelial Dysplasia: Report of 5 Illustrative Cases from Latin America

Historical Notes on Ossifying Fibroma of the Mandible

Maxillary Surgical Ciliated Cyst After Orthognathic Surgery

Revisiting the History of Odontoma, with Special Reference to Its Original Illustration

Qualitative Assessment of Collagen and Elastic Fibers in Oral Submucous Fibrosis (OSMF), OSMF with Dysplasia and Oral Squamous Cell Carcinoma Arising from OSMF: A Histochemical Study

Clinicopathological Features of Metastasis to the Oral and Maxillofacial Region—Multicenter Study

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie